Abstract
This review argues that cholecystokinin (CCK) and gastrin are incretins. The insulin cells are equipped with CCK2/gastrin receptors. CCK/gastrin peptides stimulate insulin secretion and potentiate the incretin effect of glucagon-like peptide-1. CCK/gastrin and insulin are released in significant amounts during normal mixed meals even at modest changes in blood glucose concentrations. Treatment of diabetes patients with combinatorial glucagon-like peptide-1 and CCK or gastrin-derived constructs therefore provides an expedient option.
| Original language | English |
|---|---|
| Journal | Cardiovascular Endocrinology |
| Volume | 5 |
| Issue number | 3 |
| Pages (from-to) | 99-101 |
| Number of pages | 3 |
| ISSN | 2162-688X |
| DOIs | |
| Publication status | Published - 2016 |